Search Content | UT Health San Antonio MD Anderson Cancer Center

Search Result for "Prostate Cancer"

Research & Publications

Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial

Research & Publications

Intermediate-term Risk of Prostate Cancer is Directly Related to Baseline PSA: Implications for Reducing the Burden of PSA Screening.

Research & Publications

A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation.

Story

Mays Cancer Center’s latest radiation therapy reduces treatment times, increases favorable outcomes for prostate cancer

Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, introduces the newest technology in treating prostate cancer. This innovative method is called stereotactic body radiation therapy (SBRT), a minimally invasive therapy using high amounts of radiation with millimeter precision to destroy tumors in the prostate. Stereotactic body radiation therapy is a […]

Story

UT Health San Antonio study shows MRI technique improves detection of aggressive prostate cancer

An MRI scan called restriction spectrum imaging greatly improves the detection of prostate cancer progression, according to a published study by researchers at The University of Texas Health Science Center at San Antonio, also known as UT Health San Antonio.

Clinical Trial

Validation, Calibration, and Translation of Restriction Spectrum Imaging Signal Maps to enhance MRI diagnostic capabilities in Prostate Cancer (CTMS# 22-0158)

Clinical Trial

EA8191: Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE). (CTMS# 21-0109)

Clinical Trial

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC

Clinical Trial

ORACLE: Observation of ResiduAl Cancer with Liquid biopsy Evaluation (CTMS# 22-0052)

This research is being done to see if an investigational blood test can predict whether cancer will recur (come back) after initial treatment

Clinical Trial

S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer (CTMS# 16-0138)

This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.